These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15163650)

  • 21. Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
    Balzli CL; McCormick CC; Caballero AR; Huang B; Wigington L; Smith E; Tang A; O'Callaghan RJ
    J Cataract Refract Surg; 2008 Feb; 34(2):295-301. PubMed ID: 18242457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
    Jensen MK; Fiscella RG; Moshirfar M; Mooney B
    J Cataract Refract Surg; 2008 Sep; 34(9):1460-7. PubMed ID: 18721704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
    McCulley JP; Caudle D; Aronowicz JD; Shine WE
    Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(43):960. PubMed ID: 11708594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing.
    Levine JM; Noecker RJ; Lane LC; Herrygers L; Nix D; Snyder RW
    J Cataract Refract Surg; 2004 Oct; 30(10):2177-82. PubMed ID: 15474833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
    Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
    Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model.
    Barequet IS; Habot-Wilner Z; Lavinsky F; Ziv H; Belkin M; Rosner M
    Cornea; 2007 Jun; 26(5):606-9. PubMed ID: 17525660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R
    Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fluoroquinolones against pathogenic oral bacteria.
    Núñez Otero V; Limeres Posse J; Carmona IT; Diz Dios P
    Mini Rev Med Chem; 2009 Sep; 9(10):1147-58. PubMed ID: 19534690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
    Kim DH; Stark WJ; O'Brien TP; Dick JD
    Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery.
    Güngör SG; Akova YA; Bozkurt A; Yasar Ü; Babaoğlu MÖ; Çetinkaya A; Çolak M
    Br J Ophthalmol; 2011 Sep; 95(9):1272-5. PubMed ID: 21030410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
    Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
    Heine HS; Bassett J; Miller L; Bassett A; Ivins BE; Lehoux D; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3350-7. PubMed ID: 18606841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
    Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection.
    Opal SM; Lim YP; Cristofaro P; Artenstein AW; Kessimian N; Delsesto D; Parejo N; Palardy JE; Siryaporn E
    Shock; 2011 Jan; 35(1):42-4. PubMed ID: 20523269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.
    He L; Ta CN; Miño de Kaspar H
    J Cataract Refract Surg; 2009 Oct; 35(10):1715-8. PubMed ID: 19781465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
    Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
    Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.